Natera partners with Incyte on phase II colorectal cancer study
INCY•Natera and Incyte entered a clinical collaboration for a phase II study evaluating Incyte’s investigational bispecific immunotherapy INCA33890 in stage 2/3 colorectal cancer patients after surgery and adjuvant chemotherapy.
1. Study collaboration
The trial will continue Signatera testing for up to 12 months after chemotherapy, with results incorporated as primary and secondary endpoints. Patients who test positive for molecular residual disease without radiographic evidence of disease may qualify for enrollment and treatment; the collaboration also includes trial-matching services based on Signatera results.
